ArticleJournal of Cancer2019
Research on Current Curative Expenditure among Lung Cancer Patients Based on the "System of Health Accounts 2011": Insights into Influencing Factors.
Article in Journal of Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Advancing oncology care excellence through timely, multidisciplinary-navigation models for non-palliative breast and colorectal cancer.International journal for quality in health care : journal of the International Society for Quality in Health Care · 2026Article
- Curative care expenditure across different comorbidity states of chronic hepatitis B: a prevalence study in Sichuan Province, China.BMJ open · 2025Article
- Effect of Socioeconomic Status on Financial Toxicity: The Chain Mediating Roles of Social Support and Self-Efficacy.Cancer medicine · 2025Article
- An analysis of curative care expenditure for Parkinson's disease under different comorbidity conditions: an empirical study based on China.BMC geriatrics · 2025Article
- Assessment of the financial toxicity in patients with differentiated thyroid cancer: a cross-sectional study in western China.Frontiers in public health · 2025Article
- A cost-effectiveness analysis of lung cancer screening with low-dose computed tomography and a polygenic risk score.BMC cancer · 2024Article
- Future health expenditure in the BRICS countries: a forecasting analysis for 2035.Globalization and health · 2023Article
- Financial toxicity of patients with lung cancer in China: Results from a National Survey Study.Cancer medicine · 2023Article
- Article
- [Analysis on the Incidence and Economic Burden of Patients with Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2022Article
- Case study of the beneficiary group distribution of curative care expenditure based on SHA 2011 in Xinjiang autonomous region, China.BMJ open · 2021Article
- Will the zero-margin drug policy reduce the economic burden of stroke patients in China?Journal of global health · 2021Article
- Interpretation of China's 2017 health expenditure: a latent profile analysis of panel data.BMJ open · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the total current curative expenditure (CCE) of lung cancer in Hunan Province, China under the framework of the System of Health Accounts 2011 (SHA 2011) and explore the effect of insurance status, surgery and length of stay on the hospitalization expenses of patients with lung cancer.
methodsThrough multistage stratified cluster random sampling, a total of 46,214 patients with lung cancer were enrolled from 1,072 medical institutions in Hunan Province in 2016. Under the SHA 2011 framework, the lung cancer CCE was analyzed. The relationships between hospitalization expenditure and the following factors (surgery, type of hospital, insurance status, length of stay, institution level, age and sex) were analyzed using Spearman's correlation analyses, and how these factors influenced hospital expenditure was explored through multiple stepwise regression analysis and structural equation modelling.
resultsThe CCE for lung cancer patients was 8063.75 million CNY. In total, 96.03% of the CCE for lung cancer occurred in hospitals and 58.88% of the expenditure flowed to general hospitals. The highest expenditures were incurred in the group aged 55-74 y, which accounted for 61.58% of the CCE. Drugs accounted for the greatest share expenditure to lung cancer patients at 34.31% of the CCE. Surgery, insurance status, institution level, sex and hospital type explained 57.5% of the variance in hospital expenses. The hospitalization expenses were related to surgery, insurance status, institution level and sex (rs = 0.033-0.688, p < 0.001). Surgery, insurance status and length of stay had direct effects on hospitalization expenses. Length of stay mediated the relationship between surgery and hospitalization expenses for lung cancer patients. Surgery mediated the relationship between insurance status and hospitalization expenses. All of these variables can explain 45% of the variance in hospitalization expenses.
conclusionsThe CCE of lung cancer is extremely high. The problems related to treatment efficiency and equity are serious for lung cancer patients in China. It is essential to expand health insurance coverage and reduce the curative expenditure of lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.